drugset / Trial / NCT05903274
JSP191 (briquilimab) in Subjects with LR-MDS
NaSequentialOpen-labelTreatment
Summary
A Phase 1 study in subjects with LR-MDS to assess the safety and tolerability of JSP191 as a second-line therapy.
Timeline
- Start
- 2023-06-19
- Primary completion
- 2024-10-21
- Completion
- 2024-10-21
Outcome
Outcome not reported
Stopped: “The study was terminated due to a lack of improvement in clinical efficacy outcomes.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Briquilimab | Monoclonal antibody | — | Intravenous |